These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Introduction of abortion technologies: a quality of care management approach.
    Author: Greenslade FC, Winkler J, Leonard AH.
    Journal: Law Med Health Care; 1992; 20(3):161-8. PubMed ID: 1434757.
    Abstract:
    Development of antiprogestins for use to induce early abortion clearly advances reproductive health to a higher level. A heated debate has arisen over the appropriateness of its being introduced in health care settings, however. Since the introduction of new contraceptive technologies into health care and family planning programs has produced serious shortcomings, some abortion care specialists propose a management approach to introducing RU-486/prostaglandin which stresses women's needs and preferences. This quality of care framework is based on 20 years of experience of introducing manual vacuum aspiration into developing countries. It takes into consideration that decisions about introducing RU-486/prostaglandin are country-specific and often program- or clinic-specific. Decision makers need to look at preparedness of local policy and service delivery infrastructure to take on the specific responsibilities of integrating it into ongoing programs and how this new technology will affect quality of care. The quality of care framework consists of those elements appropriate to women' access to care which include appropriate abortion care technology; technical competence of all members of the health care team at all levels of the health system; interactions between women and providers/staff (respect and support for women and nonjudgemental attitudes); comprehensive information and counseling; quality and accessible postabortion family planning and reproductive health care; and equipment, supplies, and medication. Decision makers need to consider whether RU-486/prostaglandin is acceptable to women and providers, manufactured to high standards, consistent with relevant regulatory requirements and appropriate to specific service delivery settings.
    [Abstract] [Full Text] [Related] [New Search]